HK1218373A1 - Administration of recombinant collagen for the treatment of age related disorders - Google Patents

Administration of recombinant collagen for the treatment of age related disorders

Info

Publication number
HK1218373A1
HK1218373A1 HK16104879.0A HK16104879A HK1218373A1 HK 1218373 A1 HK1218373 A1 HK 1218373A1 HK 16104879 A HK16104879 A HK 16104879A HK 1218373 A1 HK1218373 A1 HK 1218373A1
Authority
HK
Hong Kong
Prior art keywords
administration
treatment
related disorders
age related
recombinant collagen
Prior art date
Application number
HK16104879.0A
Other languages
Chinese (zh)
Inventor
Barbara Gilchrest
Original Assignee
Lotus Tissue Repair Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lotus Tissue Repair Inc filed Critical Lotus Tissue Repair Inc
Publication of HK1218373A1 publication Critical patent/HK1218373A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
HK16104879.0A 2012-12-27 2016-04-28 Administration of recombinant collagen for the treatment of age related disorders HK1218373A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261746421P 2012-12-27 2012-12-27
PCT/US2013/077479 WO2014105822A1 (en) 2012-12-27 2013-12-23 Administration of recombinant collagen 7 for the treatment of age related disorders

Publications (1)

Publication Number Publication Date
HK1218373A1 true HK1218373A1 (en) 2017-02-17

Family

ID=51022028

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16104879.0A HK1218373A1 (en) 2012-12-27 2016-04-28 Administration of recombinant collagen for the treatment of age related disorders

Country Status (7)

Country Link
US (2) US20150343026A1 (en)
EP (1) EP2938198A4 (en)
JP (1) JP2016509590A (en)
AU (4) AU2013370471A1 (en)
CA (1) CA2895503A1 (en)
HK (1) HK1218373A1 (en)
WO (1) WO2014105822A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2658766C1 (en) * 2017-04-06 2018-06-22 Общество с ограниченной ответственностью "Хеликсан Косметикс" Method for producing fish collagen hydrolyzate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004018471A (en) * 2002-06-18 2004-01-22 Shiseido Co Ltd Iv type and vii type collagen production promoter and composition for caring skin basement membrane
JP5109030B2 (en) * 2005-07-25 2012-12-26 茂 木下 Sheet-like composition
US7779000B2 (en) * 2005-08-29 2010-08-17 Microsoft Corporation Associating conditions to summary table data
EP3536325A1 (en) * 2006-11-28 2019-09-11 University Of Southern California Method for promoting wound healing
EP2443237B1 (en) * 2009-06-16 2017-02-22 CuRNA, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
EP3598976A1 (en) * 2010-05-06 2020-01-29 University Of Southern California, USC Stevens Methods and agents for enhancing wound healing
GB2485385A (en) * 2010-11-12 2012-05-16 Univ Manchester Trimeric fusion protein comprising collagen and a prokaryotic/ viral trimerisation domain
AU2012217975B2 (en) * 2011-02-14 2015-11-19 Mimedx Group Inc. Micronized placental tissue compositions and methods for making and using the same

Also Published As

Publication number Publication date
EP2938198A1 (en) 2015-11-04
AU2013370471A1 (en) 2015-07-02
AU2017218918A1 (en) 2017-10-05
JP2016509590A (en) 2016-03-31
US20180036366A1 (en) 2018-02-08
AU2021201356A1 (en) 2021-03-18
AU2017218918B2 (en) 2019-03-07
AU2019202876A1 (en) 2019-05-16
EP2938198A4 (en) 2016-07-06
AU2019202876B2 (en) 2020-12-10
CA2895503A1 (en) 2014-07-03
WO2014105822A1 (en) 2014-07-03
US20150343026A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
IL269852B (en) Combination therapies and uses for treatment of demyelinating disorders
HRP20180939T1 (en) Combination therapy for treatment of multiple sclerosis
HK1210968A1 (en) Compositions and treatment for eye diseases and disorders
IL263661A (en) Combination therapy for the treatment of glioblastoma
EP2575816A4 (en) Combination therapy for skin disorders
EP2906208A4 (en) Therapeutic treatment
ZA201407532B (en) Therapeutic uses of fibroblast growthfactor 21 proteins
IL235058A0 (en) Pharmaceutical combinations for the treatment of metabolic disorders
HK1212253A1 (en) Combinations of modalities for the treatment of diabetes
IL233061A0 (en) Recombinant human alpha-1-antitrypsin for the treatment of inflammatory disorders
HK1204452A1 (en) Treatment for bone diseases
HK1204573A1 (en) Treatment of inflammatory skin disorders
HK1215794A1 (en) Allogeneic autophagosome-enriched composition for the treatment of disease
HK1219224A1 (en) Therapeutic agent for keratoconjunctive disorders
HK1218373A1 (en) Administration of recombinant collagen for the treatment of age related disorders
AU2012900788A0 (en) Combination treatment for rheumatic disorders
GB201303721D0 (en) Compositions for treatment of sleep disorders
GB201204645D0 (en) Treatment of disease
GB201207363D0 (en) Compounds for the treatment of metabolic disorders
GB201207359D0 (en) Compounds for the treatment of metabolic disorders
EP2531186A4 (en) Treatment skin disorders